Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer
Randomized, placebo-controlled study confirms ramucirumab, in combination with docetaxel, significantly extended progression-free survival (PFS) in patients with platinum-refractory advanced urothelia...
Page (1) of 1 - 09/10/17||
(September 10, 2017)
This article is no longer available,but here are some related topics.
USA,Medicine,Disease,Surgery,healthcare,medical technologists,Pregnancy,Cancer,Surgery,Medication,Womens Health,Pregnancy,Science,Medical,Biology,Cancer,Other,Women,
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved